Rocket Pharmaceuticals (RCKT)
(Delayed Data from NSDQ)
$16.98 USD
+0.33 (1.98%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $17.00 +0.02 (0.12%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth D Momentum F VGM
Price, Consensus and EPS Surprise
RCKT 16.98 +0.33(1.98%)
Will RCKT be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for RCKT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RCKT
RCKT Completes Enrollment in Rare Heart Disease Study, Stock Rises
Rocket Stock Down More Than 30% in Past Six Months: Here's Why
RCKT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Rocket Pharmaceuticals (RCKT) Down 10.6% Since Last Earnings Report: Can It Rebound?
Biotech Stock Roundup: GSK, CVAC Revise Agreement, Updates From MRNA, RNAC & More
FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease
Other News for RCKT
RTW INVESTMENTS, LP Reduces Stake in Allurion Technologies Inc
Disney initiated, Cisco upgraded: Wall Street's top analyst calls
Rocket Pharmaceuticals initiated with bullish view at Scotiabank, here's why
Biotech Alert: Searches spiking for these stocks today
Rocket: Danon Disease Treatment Program Should Carry The Tide Until Regulatory Moves